UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Annals of oncology, 2018-04, Vol.29 (4), p.945-952

2018

Volltextzugriff (PDF)

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Annals of oncology, 2024-02, Vol.35 (2), p.190-199

2024

Volltextzugriff (PDF)

NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis

Annals of oncology, 2019-06, Vol.30 (6), p.953-962

2019

Volltextzugriff (PDF)

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients

Annals of oncology, 2017-04, Vol.28 (4), p.868-873

2017

Volltextzugriff (PDF)

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of oncology, 2021-01, Vol.32 (1), p.85-96

2021

Volltextzugriff (PDF)

The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients

Annals of oncology, 2009-05, Vol.20 (5), p.897-905

2009

Volltextzugriff (PDF)

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2011-07, Vol.22 (7), p.1622-1627

2011

Volltextzugriff (PDF)

119P A pan-cancer study on difference of homologous recombination deficiency and tumour mutational burden between Chinese and Western patients

Annals of oncology, 2020-09, Vol.31, p.S288-S288

2020

Volltextzugriff (PDF)

Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma

Annals of oncology, 2019-06, Vol.30 (6), p.990-997

2019

Volltextzugriff (PDF)

Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial

Annals of oncology, 2022-10, Vol.33 (10), p.1061-1070

2022

Volltextzugriff (PDF)

LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study

Annals of oncology, 2021-09, Vol.32, p.S1331-S1331

2021

Volltextzugriff (PDF)

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

Annals of oncology, 2017-07, Vol.28 (7), p.1495-1507

2017

Volltextzugriff (PDF)

Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy

Annals of oncology, 2020-06, Vol.31 (6), p.769-779

2020

Volltextzugriff (PDF)

IQGAP3 overexpression correlates with poor prognosis and radiation therapy resistance in breast cancer

Annals of oncology, 2018-11, Vol.29, p.ix10-ix11

2018

Volltextzugriff (PDF)

Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma

Annals of oncology, 2024-02, Vol.35 (2), p.211-220

2024

Volltextzugriff (PDF)

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Annals of oncology, 2021-03, Vol.32 (3), p.384-394

2021

Volltextzugriff (PDF)

1560P Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models

Annals of oncology, 2023-10, Vol.34, p.S873-S873

2023

Volltextzugriff (PDF)

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma

Annals of oncology, 2019-09, Vol.30 (9), p.1514-1520

2019

Volltextzugriff (PDF)

1280P Analysis of ARID1A and ARID1B as potential biomarkers for NSCLC immunotherapy

Annals of oncology, 2020-09, Vol.31, p.S827-S827

2020

Volltextzugriff (PDF)

480P Comprehensive genomic and clinical analysis of adolescents and young adults with colorectal cancer

Annals of oncology, 2020-09, Vol.31, p.S445-S445

2020

Volltextzugriff (PDF)

Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: A prospective clinical trial

Annals of oncology, 2018-11, Vol.29, p.ix95-ix95

2018

Volltextzugriff (PDF)

330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies

Annals of oncology, 2023-11, Vol.34, p.S1599-S1600

2023

Volltextzugriff (PDF)

521P Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research

Annals of oncology, 2023-11, Vol.34, p.S1674

2023

Volltextzugriff (PDF)

The landscape of kinase fusions in 445 Chinese NSCLC patients

Annals of oncology, 2017-10, Vol.28, p.vii16-vii16

2017

Volltextzugriff (PDF)

1243P Influence of home nutritional therapy on body weight in patients with esophageal cancer after surgery: A prospective observational study

Annals of oncology, 2022-09, Vol.33, p.S1117

2022

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Aktive Filter

ThemaPhysics

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(121)

Sprache

Englisch
(121)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(12)
Oncology
(12)
Science & Technology
(12)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Adult
(4)
Female
(4)
Male
(4)
Middle Aged
(4)
Neoplasm Staging
(4)
Aged
(3)
Mucosal Melanoma
(3)
Prognosis
(3)
Toripalimab
(3)
Treatment Outcome
(3)
Aged, 80 And Over
(2)
Antibodies, Monoclonal, Humanized
(2)
Antineoplastic Agents
(2)
Axitinib
(2)
Axitinib - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

119P A pan-cancer study on difference of homologous recombination deficiency and tumour mutational burden between Chinese and Western patients

Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma

Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial

LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy

IQGAP3 overexpression correlates with poor prognosis and radiation therapy resistance in breast cancer

Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

1560P Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma

1280P Analysis of ARID1A and ARID1B as potential biomarkers for NSCLC immunotherapy

480P Comprehensive genomic and clinical analysis of adolescents and young adults with colorectal cancer

Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: A prospective clinical trial

330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies

521P Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research

The landscape of kinase fusions in 445 Chinese NSCLC patients

1243P Influence of home nutritional therapy on body weight in patients with esophageal cancer after surgery: A prospective observational study

Aktive Filter

Suchergebnisse filtern